Browsing by Author "Tripathi, Neeraj"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    A Comparative Study Of Dapagliflozin And Pioglitazone In Improving Hepatic Enzymes And Hepatic Steatosis In Type 2 Diabetes Mellitus With Non-Alcoholic Steatohepatitis.
    (Indian Society for Health and Advanced Research, 2025-06) Balgir, Inderpreet Singh; Singh, R. R; Maheshwari, Anuj; Tripathi, Neeraj; Tiwari, C. S; Balgir, Parminder Kaur; Malhotra, Vishal
    Introduction: Non-alcoholic fatty liver disease (NAFLD) is a major liver disease worldwide. The individuals are at increased risk of hepatic and extra-hepatic morbidity and mortality. Non-alcoholic steatohepatitis (NASH) is an active form of NAFLD and is associated with type 2 diabetes mellitus (DM) and obesity. Therefore, the current study was undertaken to determine the effect of dapagliflozin (DAPA) versus pioglitazone (PIO) on liver enzymes, changes in liver fat and body composition. Methods: The study was conducted with type2 DM patients visiting medicine OPD as per the inclusion and exclusion criteria by randomly assigning either the DAPA (group A, n = 40) or the PIO (group B, n = 40) who were already on OHA. At 0 week, all the baseline investigations including X-ray chest, ECG, and fibroscan were done and repeated after 24 weeks after taking the drugs, and changes were compared. DAPA and PIO showed equivalent beneficial effects on NAFLD/NASH in patients with type 2 DM inResults: metabolic parameters like FBS, Postprandial and HbA1c and liver enzymes, liver stiffness, in spite of their different mechanism of actions. The comparison between the two groups was statistically non-significant. DAPA decreased body composition and liver fat, where the results were highly significant as compared to PIO. PIO decreased liver stiffness, but there was an increase in body weight, and was highly significant as compared to DAPA. DAPA is the preferred drug of choice for better glycaemic control and hepatic steatosis in obese patients withConclusion: type 2 DM with NAFLD/NASH.